Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2009-01-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash reconciliation, payments to directors, financing facilities, and compliance statements. It covers a quarter ended 31 December 2008 and includes substantive financial data and analysis for that period. The document is over 7,000 characters, indicating it is a full report rather than a brief announcement. Appendix 4C is a known quarterly cash flow report format used in Australian stock exchange filings, which aligns with an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2009
2009-01-29 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, reconciliation of cash, and compliance statements. The report is for the quarter ended 30 September 2008. The presence of detailed quarterly financial data and cash flow statements indicates this is a comprehensive financial report for a period shorter than a full fiscal year. The document is about 7994 characters long, which is sufficient to contain substantive financial data rather than just an announcement or certification. The document matches the definition of an Interim / Quarterly Report (IR) as it provides actual financial statements and analysis for a quarter. Therefore, the correct classification is IR. Q1 2009
2008-10-30 English
PRESENTATION TO ANNUAL GENERAL MEETING 23 pages ?Kb
AGM Information Classification · 100% confidence The document is a presentation titled 'PRESENTATION TO ANNUAL GENERAL MEETING' dated 13 October 2008, addressed to the Australian Stock Exchange. It includes detailed slides about the company's drug development pipeline, clinical trial progress, financial summary, and business strategy. The content is clearly intended for shareholders at the AGM and is a presentation material rather than a full report or announcement of voting results. The length is substantial (15,000 characters), and the document is not merely an announcement of a report publication or a certification. Therefore, it fits the definition of AGM Information (AGM-R).
2008-10-12 English
Results of Meeting 2 pages ?Kb
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a communication to the Australian Stock Exchange regarding the results of resolutions passed at the company's Annual General Meeting (AGM) held on 13 October 2008. It includes voting results for resolutions such as adoption of the Remuneration Report and re-election of directors. The document also contains the Notice of Annual General Meeting with agenda items. The document length is short (2198 characters) and it primarily reports on the AGM proceedings and voting outcomes rather than providing the full annual report or financial statements. Therefore, it is best classified as Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at general meetings.
2008-10-12 English
Annual Report/Notice of Annual General Meeting/Proxy Form 45 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Annual Report' and is addressed as the Company's Annual Report for the year ended 30 June 2008. It includes detailed sections such as Operating and Financial Review, Directors' Report, Income Statement, Balance Sheet, Statement of Cash Flows, Notes to Financial Statements, Directors' Declaration, and Independent Audit Report. The content covers comprehensive financial performance, business progress, clinical development updates, and corporate governance information. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2008
2008-09-14 English
BIT225 Highly Synergistic with New Class of Anti-HCV Therapy 2 pages ?Kb
Capital/Financing Update Classification · 85% confidence The document is a short announcement from Biotron Limited dated 9 September 2008, addressed to the Australian Stock Exchange. It discusses the results of a study on the company's antiviral drug BIT225, highlighting its synergistic effects with other Hepatitis C therapies. The document is only 4700 characters long and contains no financial statements, detailed financial data, or comprehensive report content. It is a corporate announcement about a scientific/clinical development rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention the release or availability of a report. The content is primarily a business update on drug development progress, which is typical of a Capital/Financing Update or general corporate announcement. Given the focus on drug development progress and synergy with other therapies, and the announcement nature, the best fitting category is Capital/Financing Update (CAP), which often includes updates on company progress that could impact valuation and financing.
2008-09-08 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.